Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Patients can now get the starting 2.5 mg dose for $299 per month
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
